98%
921
2 minutes
20
This study evaluated the prevalence, incidence, and relative risk of comorbid atopic dermatitis (AD) among patients with alopecia areata (AA) using data from the Merative MarketScan Research Databases. Eligible patients had ≥1 inpatient or ≥2 outpatient claims for AA between January 1, 2017 and October 31, 2023; were aged ≥12 years; and were continuously enrolled during the ≥5-year baseline period through the 6-month follow-up period; index date was the earliest date of AA diagnosis. AD prevalence (%) and incidence (cases per 1000 person-years) among patients with AA are reported and stratified by disease severity; a subgroup analysis was performed among adolescents (aged 12-17 years). Adjusted hazard ratios for being diagnosed with AD are reported for patients with moderate-to-severe versus those with mild AA. Prevalence of AD among patients with AA at baseline was 3.2% (overall prevalence in database: 12.1%), with most having moderate-to-severe AD; prevalence was higher among adolescents with AA (7.6%). Incidence of AD increased with AA disease severity, regardless of age. Those with moderate-to-severe AA had 78% higher risk of being diagnosed with AD than those with mild disease. Dermatologist-diagnosed patients had higher rates of comorbid AD regardless of AA severity. These data demonstrate the importance of increased risk of comorbid AD when making treatment decisions for patients with AA.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jid.2025.06.1578 | DOI Listing |
J Invest Dermatol
September 2025
Department of Dermatology, Keck School of Medicine of University of South California, Los Angeles, California, USA; Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan. Electronic address:
This review examines the roles of galectins, a family of animal lectins, in inflammatory skin diseases, focusing on their involvement in the pathogenesis of psoriasis, atopic dermatitis, contact dermatitis, and common autoimmune diseases. We highlight the differential expression of galectins in lesional skin and their correlation with inflammatory mediators. In addition, we summarize the functions and mechanisms of action of endogenous galectins, as revealed through studies of genetically engineered cell lines and experimental animals.
View Article and Find Full Text PDFJ Invest Dermatol
September 2025
Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; Sibel Health, Chicago, Illinois, USA; Querrey Simpson Institute for Bioelectronics, Northwestern University, Evanston, Illinois, USA. Electronic address:
The integration of wearable medical devices and digital health technologies (DHTs) in health care has grown significantly during the past 2 decades, particularly in dermatology, in which objective measurement of symptoms such as itch remains challenging. This review examines the evolution of DHTs in dermatology, focusing on the validation frameworks necessary for their implementation in clinical trials and research. We discuss the key stages of validation: hardware validation to ensure device reliability, analytical validation to transform raw sensor data into meaningful metrics, and clinical validation to demonstrate utility in specific patient populations.
View Article and Find Full Text PDFClin Exp Dermatol
September 2025
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Sleep
September 2025
Instituto do Sono, Associação Fundo de Incentivo à Pesquisa (AFIP), São Paulo, Brazil.
J Vet Pharmacol Ther
September 2025
Elanco Animal Health, Sèvres, France.
Ilunocitinib, a novel Janus kinase inhibitor, is indicated for managing pruritus and skin lesions associated with canine allergic and atopic dermatitis. Pharmacokinetics of ilunocitinib were investigated following single intravenous and oral administrations, both in fed and fasted states. Dose proportionality was assessed using oral doses ranging from 0.
View Article and Find Full Text PDF